[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466636":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":50,"locationsCount":51},{"fullName":5,"class":6},"Zentrum fur Humangenetik Tuebingen","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Vaccination","Personalized neoantigen vaccination",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Saskia Biskup, Dr. Dr.","CONTACT","+49 (0)7071 565 44 00","Saskia.Biskup@humangenetik-tuebingen.de",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Zentrum für Humangenetik Tübingen","AVAILABLE","Tübingen","Germany","DE",{"type":27,"coordinates":28},"Point",[29,30],9.05222,48.52266,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100466636","glioblastoma-and-individualized-therapies-100466636",false,"NCT05356312","Glioblastoma and Individualized Therapies","Retrospective Analysis of Glioblastoma Patients With Immune Therapies","Inclusion Criteria:\n\n* malignant glioma, IDH WT\n\nExclusion Criteria:\n\n* na","ALL","EXPANDED_ACCESS","The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio \u002F chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.",[45],"Glioma, Malignant","2024-02-29",{"date":48,"type":49},"2024-03-01","ACTUAL",{"name":5,"class":6},1]